PTCT 250516 37.00C(PTCT250516C37000) Stock Price Today

US OptionsDetailed Quotes

PTCT250516C37000

Watchlist

1.87
+0.37+24.67%

15min DelayClose May 6 16:00 ET

1.87High1.50Low

Intraday

5D
Daily

News

PTC Therapeutics Swings to Q1 Earnings, Revenue Increases
MT Newswires03:55 ET
Scotiabank Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Maintains Target Price $55
Moomoo News03:33 ET · Ratings
TD Cowen Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Cuts Target Price to $52
Moomoo News03:33 ET · Ratings
Express News | PTC Therapeutics Inc : Leerink Partners Cuts Target Price to $48 From $52
Reuters01:14 ET
PTC Therapeutics Projects $650M to $800M Revenue for 2025 Amid Global SUFIANCE Launch Preparations
Seeking Alpha23:20 ET
PTC Therapeutics: Balancing Strategic Success With Regulatory Uncertainty – A Hold Rating Analysis
TipRanks20:35 ET · Ratings

Comments

Jerry Kronenberg

Yesterday 04:37

Columns Wall Street Today: S&P 500 Snaps Nine-Session Winning Streak as Nasdaq and DJIA Also Fall

The S&P 500 snapped its longest winning streak in 20 years on Monday as markets inched lower amid a little significant tariff news, coupled with caution ahead of the Federal Reserve's rate decision due out Wednesday.
The $S&P 500 Index (.SPX.US)$ shed 36.29 points (0.6%) to close at 5,650.38, halting a run of consecutive positive sessions at nine – the index's longest winning streak since 2004.
The $Nasdaq Composite Index (.IXIC.US)$ likewise ...

FOMC countdown: Inflation vs. growth – How will Powell play his hand?

Teddy123

May 5 19:08

PTC518 PIVOT-HD Study Achieves Primary Endpoint

$PTC Therapeutics (PTCT.US)$
Breakthrough: PTC518 Shows 39% HTT Reduction in Huntington's Disease Trial, Potential First Disease-Modifying Treatment

Teddy123

Mar 20 20:26

PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

$PTC Therapeutics (PTCT.US)$
Breakthrough PKU Treatment Enables 126% Higher Protein Intake in Clinical Trial

Teddy123

Feb 19 20:27

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

$PTC Therapeutics (PTCT.US)$
Could This Rare Disease Drug Be PTC's Next Breakthrough? FDA Priority Review Reveals Major Potential

Lnova

Dec 20, 2024 07:24

$PTC Therapeutics (PTCT.US)$
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
12/19/2024 08:00AM ET
- If approved, vatiquinone would be the first and only authorized therapy for children with FA -
- PTC's fourth approval application submitted to FDA in 2024 -
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) ...